| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 9921404 | European Journal of Pharmacology | 2005 | 8 Pages |
Abstract
In summary, our data demonstrated that CS-866 was effective in early and late stage retinopathy models through the inhibition of the angiotensin AT1 receptor. These findings suggest the possibility of CS-866 as a therapeutic agent for diabetic retinopathy.
Keywords
Related Topics
Life Sciences
Neuroscience
Cellular and Molecular Neuroscience
Authors
Hiroaki Nakamura, Tatsuya Inoue, Naohisa Arakawa, Yuki Shimizu, Yasushi Yoshigae, Izumi Fujimori, Emi Shimakawa, Tohru Toyoshi, Tomihisa Yokoyama,